https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-722012-12-15 00:00:002019-02-15 08:49:50The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-11 / Biol. Pharm. Bull. 2013;36(3):376-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-11 / Biol. Pharm. Bull. 2013;36(3):376-832012-12-11 00:00:002012-12-11 00:00:00Short-term hyperthermia promotes the sensitivity of MCF-7 human breast cancer cells to paclitaxel
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-01 / Curr Drug Discov Technol 2012 Dec;9(4):237-55
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-01 / Curr Drug Discov Technol 2012 Dec;9(4):237-552012-12-01 00:00:002019-02-15 08:59:35Immunotherapy with tumor vaccines for the treatment of malignant gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-01 / Clin. Exp. Immunol. 2012 Dec;170(3):291-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-01 / Clin. Exp. Immunol. 2012 Dec;170(3):291-92012-12-01 00:00:002019-02-15 08:48:38Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-21 / Clin Transl Oncol 2013 Feb;15(2):95-105
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-21 / Clin Transl Oncol 2013 Feb;15(2):95-1052012-11-21 00:00:002019-02-15 09:17:14Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Oncoimmunology 2012 Nov;1(8):1401-1403
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Oncoimmunology 2012 Nov;1(8):1401-14032012-11-01 00:00:002019-02-15 08:39:52Targeting cancer stem cells via dendritic-cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / J. Cell. Mol. Med. 2012 Nov;16(11):2827-37
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / J. Cell. Mol. Med. 2012 Nov;16(11):2827-372012-11-01 00:00:002019-02-15 08:39:53Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Curr. Mol. Med. 2012 Nov;12(9):1183-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Curr. Mol. Med. 2012 Nov;12(9):1183-972012-11-01 00:00:002019-02-15 09:17:15Heat shock proteins (HSPs) based anti-cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Clin. Exp. Immunol. 2012 Nov;170(2):167-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Clin. Exp. Immunol. 2012 Nov;170(2):167-772012-11-01 00:00:002019-02-15 08:50:42Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Gan To Kagaku Ryoho 2012 Nov;39(12):1766-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Gan To Kagaku Ryoho 2012 Nov;39(12):1766-92012-11-01 00:00:002012-11-01 00:00:00[Immunotherapy with hyperthermia for advanced or recurrent breast cancer patients in whom standard therapy showed no effect or was refused]
